Pomalidomide and Dexamethasone Treatment for ≥ 1 Year in Renally Impaired Patients With Relapsed or Refractory Multiple Myeloma

Authors :: Arnaud Jaccard
Javier de la Rubia
Pieter Sonneveld
Katja Weisel
Mark Cook
Pamela Bacon
Niels W.C.J. van de Donk
Maria Theresa Krauth
Elisabeth Kueenburg
Meletios A. Dimopoulos
Barbara Rosettani
Karthik Ramasamy
Margaret Atiba-Davies
Antonio Ardizzoia
Antonia Di Micco
Source :: Clinical Lymphoma Myeloma and Leukemia. 19:e284-e285
Publication Year :: 2019
Publisher :: Elsevier BV, 2019.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
Internal medicine
medicine
Refractory Multiple Myeloma
Hematology
business
Pomalidomide
Dexamethasone
medicine.drug

Tools